These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Park TS; Rosebury W; Kindt EK; Kowala MC; Panek RL Pharmacol Res; 2008 Jul; 58(1):45-51. PubMed ID: 18611440 [TBL] [Abstract][Full Text] [Related]
4. Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. Glaros EN; Kim WS; Quinn CM; Jessup W; Rye KA; Garner B J Lipid Res; 2008 Feb; 49(2):324-31. PubMed ID: 17978313 [TBL] [Abstract][Full Text] [Related]
5. Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. Glaros EN; Kim WS; Rye KA; Shayman JA; Garner B J Lipid Res; 2008 Aug; 49(8):1677-81. PubMed ID: 18467744 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice. Bietrix F; Lombardo E; van Roomen CP; Ottenhoff R; Vos M; Rensen PC; Verhoeven AJ; Aerts JM; Groen AK Arterioscler Thromb Vasc Biol; 2010 May; 30(5):931-7. PubMed ID: 20167657 [TBL] [Abstract][Full Text] [Related]
7. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. Hojjati MR; Li Z; Zhou H; Tang S; Huan C; Ooi E; Lu S; Jiang XC J Biol Chem; 2005 Mar; 280(11):10284-9. PubMed ID: 15590644 [TBL] [Abstract][Full Text] [Related]
8. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Park TS; Panek RL; Rekhter MD; Mueller SB; Rosebury WS; Robertson A; Hanselman JC; Kindt E; Homan R; Karathanasis SK Atherosclerosis; 2006 Dec; 189(2):264-72. PubMed ID: 16458317 [TBL] [Abstract][Full Text] [Related]
9. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice. Davis HR; Hoos LM; Tetzloff G; Maguire M; Zhu LJ; Graziano MP; Altmann SW Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):841-9. PubMed ID: 17218600 [TBL] [Abstract][Full Text] [Related]
10. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice. Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327 [TBL] [Abstract][Full Text] [Related]
11. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Umehara T; Sudoh M; Yasui F; Matsuda C; Hayashi Y; Chayama K; Kohara M Biochem Biophys Res Commun; 2006 Jul; 346(1):67-73. PubMed ID: 16750511 [TBL] [Abstract][Full Text] [Related]
12. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412 [TBL] [Abstract][Full Text] [Related]
13. Serine palmitoyltransferase (SPT) deficient mice absorb less cholesterol. Li Z; Park TS; Li Y; Pan X; Iqbal J; Lu D; Tang W; Yu L; Goldberg IJ; Hussain MM; Jiang XC Biochim Biophys Acta; 2009 Apr; 1791(4):297-306. PubMed ID: 19416652 [TBL] [Abstract][Full Text] [Related]
14. Effects of sphingolipid synthesis inhibition on cholesterol gallstone formation in C57BL/6J mice. Lee BJ; Kim JS; Kim BK; Jung SJ; Joo MK; Hong SG; Kim JS; Kim JH; Yeon JE; Park JJ; Byun KS; Bak YT; Yoo HS; Oh S J Gastroenterol Hepatol; 2010 Jun; 25(6):1105-10. PubMed ID: 20594226 [TBL] [Abstract][Full Text] [Related]
15. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Miyake Y; Kozutsumi Y; Nakamura S; Fujita T; Kawasaki T Biochem Biophys Res Commun; 1995 Jun; 211(2):396-403. PubMed ID: 7794249 [TBL] [Abstract][Full Text] [Related]
16. Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity? Tabas I Circulation; 2004 Nov; 110(22):3400-1. PubMed ID: 15569847 [No Abstract] [Full Text] [Related]
17. Lack of evidence for antiatherogenic effects of wheat bran or corn bran in apolipoprotein E-knockout mice. Zhao Z; Xu Z; Le K; Azordegan N; Riediger ND; Moghadasian MH J Agric Food Chem; 2009 Jul; 57(14):6455-60. PubMed ID: 19601675 [TBL] [Abstract][Full Text] [Related]
18. Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein E deficient mice. Xiao HB; Yang ZC; Jia SJ; Li NS; Jiang DJ; Zhang XH; Guo R; Zhou Z; Deng HW; Li YJ Life Sci; 2007 Jun; 81(1):1-7. PubMed ID: 17532008 [TBL] [Abstract][Full Text] [Related]
19. A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet. Ueshima K; Akihisa-Umeno H; Nagayoshi A; Takakura S; Matsuo M; Mutoh S Eur J Pharmacol; 2004 Oct; 501(1-3):137-42. PubMed ID: 15464072 [TBL] [Abstract][Full Text] [Related]
20. Swimming reduces the severity of atherosclerosis in apolipoprotein E deficient mice by antioxidant effects. Okabe TA; Shimada K; Hattori M; Murayama T; Yokode M; Kita T; Kishimoto C Cardiovasc Res; 2007 Jun; 74(3):537-45. PubMed ID: 17374527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]